Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
AM Best Named a 2026 Top Workplace in the United States
-
Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Ne
-
Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
-
Creao AI Raises $10M to Build the Platform Where One Person Does the Work of a Team
-
Asgard Therapeutics to present preclinical data on lead asset AT-108, a personalized, off-the-shelf gene therapy, at AACR Annual Meeting 2026
-
Accent Therapeutics Presents Data Reinforcing Therapeutic Potential of Novel KIF18A Inhibitor, ATX-295, at the 2026 American Association for Cancer Research Annual Meeting
-
SingleCell Biotechnology Presents Data at AACR Annual Meeting Demonstrating High-Throughput Single-Cell Assay Linking Clonal Growth Phenotypes to Molecular Profiles
-
Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
-
Meiji Holdings Co., Ltd. Highlights that Yogurt Containing Bacteria Metabolite Shows a Tendency Toward Higher Response When Added to Immune Checkpoint Inhibitor Therapy in People Living with Non-small
-
Crestwood Advisors Named Once Again to USA TODAY’s 2026 Best Financial Advisory Firms List
-
Salubris Biotherapeutics Presents Phase 1/2 Dose Escalation and Expansion Cohort Data for JK06, 5T4-Targeted Antibody Drug Conjugate, at the American Association for Cancer Research Annual Meeting
-
Nested Therapeutics Reports Initial Encouraging Clinical Activity and Favorable Tolerability of NST-628, a Brain-Penetrant Pan-RAF/MEK Molecular Glue, at AACR 2026
-
intoDNA Presents Data on Two Novel Assays, sSTRIDE-NER and sSTRIDE-PARP1, in Poster Presentations at the 2026 AACR Annual Meeting
-
Orum Therapeutics Presents New Preclinical Data at AACR 2026 on ORM-1153, a CD123-Targeting Degrader-Antibody Conjugate, Highlighting Broad Activity in Acute Myeloid Leukemia and the Potential for Imp
-
Soley Therapeutics Presents Preclinical Data Demonstrating Selective Anti-Tumor Activity of STX-6398, a First-in-Class CKAP2 Modulator, at AACR 2026
-
Akamis Bio Announces Encouraging Preliminary Results from the Phase 1b FORTRESS Study of NG-350A in Mismatch Repair-Proficient Locally Advanced Rectal Cancer
-
OncoNano to Present New Preclinical Data at AACR 2026 Highlighting Effective Tumor Delivery Enabled by ON-BOARD™ Platform
-
Lunit to Present Six AI Studies at AACR 2026 Highlighting Advances in Precision Oncology and Real-World Clinical Application
-
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection
-
NEOK Bio Presentations at AACR 2026 Annual Meeting Showcase Potential of a Differentiated Bispecific Antibody Drug Conjugate Pipeline
-
Study Finds AI Medical Diagnosis Errors Exceed 80%
-
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer
-
Biolojic Design Presents New Preclinical Data for BD200, a First-in-Class Multibody-Drug Conjugate Targeting Trop-2 and Nectin-4 at the American Association of Cancer Research Annual Meeting
-
Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform
-
Pheast Therapeutics Reports Initial Phase 1a Data Showing Early Clinical Activity and Target Engagement for PHST001 at AACR 2026
-
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
-
New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma
-
Moderna to Present Phase 1/2 Data on Its Investigational Cancer Antigen Therapy mRNA-4359 as First-Line Therapy in Combination with Pembrolizumab in Locally Advanced or Metastatic Melanoma at the 2026
-
New ACP Breast Cancer Screening Guidelines Are a Step Backward that May Cost Lives
-
Cegedim: Release of its 2025 Universal Registration Document
-
Marcus & Millichap Closes Two Westside Los Angeles Multifamily Sales at Record Value
-
Renewables on the Rise in the US Despite Opposition from Trump
-
Nissan Unveils Plan to Transform Vehicular Mobility Using AI
-
Ohio No. 1 State in the Midwest for Business, According to CEOs Nationwide
-
Dr. Ronald Bernardini Opens Doors for Future Health Professionals With Nationwide Undergraduate Scholarship Initiative
-
Americans are Supplementing Healthcare Visits with AI, Gallup Survey Finds
-
Toll Brothers Announces Final Luxury Home for Sale at Freestone Station in Marietta, Georgia
-
Unicoin Foundation Debuts, Aligning Social Impact with the Future of Responsible Crypto
-
PSEG Long Island Celebrates National Lineworker Appreciation Day
-
403 Auction Launches Star Trek Universe 60th Anniversary Sale in Toronto Featuring Set Items
-
JimStoppani.com Announces Summer Shred Challenge with $25,000 Grand Prize
-
2026 Skagit Valley Tulip Festival Reaches Full Bloom Across Skagit County
-
Power Life Endorsed by Brooke Burke, Launches Superfood Daily Blend: A Plant-Based Superfood Greens Powder for Clean Energy, Digestive Health, and Balanced Vitality
-
Annals of Internal Medicine presents breaking scientific news at ACP's Internal Medicine Meeting 2026
-
New guidance from ACP says all average-risk females aged 50-74 should undergo biennial mammography screening for breast cancer
-
Hillsdale College’s First Feature-Length Documentary ‘Revolutionary America’ Coming to Theatres from Fathom Entertainment May 31 – June 2
-
University of Maryland and American University Students Inspire Transportation Innovation in Maryland
-
The Melanoma Research Foundation Launches its Inaugural Washington DC 5K Fundraiser with a Goal of $115,000 in Support of Melanoma Research, Education and Advocacy
-
Woodside Tugboat Contract Boosts Louisiana Spend to $1 Billion
-
Dime to Release Earnings on April 23, 2026

